Evidence map›Paper›PMID 41007616›Full record

ArticleBiomedicines2025

In Vivo Characterization of ONL1204, a Small Peptide Inhibitor of the Fas Receptor, as a Potential Neuroprotective Therapy for Geographic Atrophy and Dry Age-Related Macular Degeneration.

Andrew J Kocab, Marisol Cano, Marianna Bacellar-Galdino, Jeffrey A Jamison, William J Brock, David N Zacks, James T Handa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew J KocabONL Therapeutics, Inc., Ann Arbor, MI 48104, USA.ORCID 0000-0001-6069-2166
Marisol CanoWilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA.
Marianna Bacellar-GaldinoAltasciences, Scott Township, PA 18411, USA.ORCID 0000-0002-8765-4466
Jeffrey A JamisonOcular Consultants, Inc., Livonia, MI 48154, USA.ORCID 0009-0000-3472-3467
William J BrockBrock Scientific Consulting, LLC, Hilton Head, SC 29926, USA.
David N ZacksONL Therapeutics, Inc., Ann Arbor, MI 48104, USA.
James T HandaWilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0003-1314-1745

Funding

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMDR42EY029625 · NEI · ONL THERAPEUTICS, INC. · PI HANDA, JAMES T, KOCAB, ANDREW JOSEPH · 2018 to 2022
$1.4M
NEI NIH HHS R42 EY029625NIH HHS 5R42EY029625-23
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

age-related macular degenerationanimal modelsCD95Fasgeographic atrophyneuroprotection

Identifiers

PMID41007616
PMCPMC12467535

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.